Search

Fezolinetant

[A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … effective treatments for VMS by relieving symptoms in as many as 95% of menopausal women.

Mumps virus strain B level jeryl lynn live antigen

It is an active immunization against mumps, which is a common childhood disease.

Xamoterol

It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors. … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients.

Potassium acetate

Potassium sulfate

Methylergometrine

(Merck Index, 11th ed)

Tetraethylammonium

Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential therapeutic vasodilator but serious toxic effects were found. … The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued.

Agalsidase beta

[A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

Volixibat

According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments … If approved for use, it will be the first available agent for the treatment of NASH.

Demegestone

Demegestone is a progesterone receptor agonist that was previously used to treat luteal insufficiency. It was previously marketed in France as Lutionex, but has since been discontinued.